Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Trial details
- Registry ID
- NCT05270460
- Drugs studied
- PCS12852
TrialRedline tracks 3 clinical trials sponsored by Processa Pharmaceuticals: 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe GastroparesisNCT05270460 | PCS12852 | Completed | 2022-09-29Actual |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692 | Capecitabine, PCS6422 and capecitabine | Terminated | 2026-07-29Actual |
| A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaNCT04800562 | PCS499 | Terminated | 2023-02-28Actual |
Names as written in the registry records.
NCT05270460 · Processa Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate Description: Change from baseline in gastric emptying rate was determined by the AUC by Gastric Emptying Breath Test (GEBT) at Day 28 after administration of PCS12852 or placebo. Time frame: ~28 days Measure: Change in Gastric Emptying Rate From Baseline Using t50 Metric for Gastric Emptying Rate Description: Time for 50% gastric emptying (t50) metric assessed by the GEBT Time frame: ~28 days Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28 Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28. After: Measure: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate Description: Change from baseline in gastric emptying rate was determined by the AUC by Gastric Emptying Breath Test (GEBT) at Day 28 after administration of PCS12852 or placebo. Time frame: ~28 days Measure: Change in Gastric Emptying Rate From Baseline Description: Time for 50% gastric emptying (t50) metric assessed by the GEBT Time frame: ~28 days Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28 Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28.
NCT06568692 · Processa Pharmaceuticals
Before: Estimated. After: Actual.
Before: 90 participants (planned). After: 20 participants (actual).
Before: Estimated. After: Actual.
Before: Sep 2026. After: 29 Jul 2026.
Before: Recruiting. After: Terminated.